Overview

Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
First Hospital of Jilin University
The First Hospital of Jilin University
Treatments:
Interferons